WO1996009839A1 - Preparation d'immunoglobuline - Google Patents

Preparation d'immunoglobuline Download PDF

Info

Publication number
WO1996009839A1
WO1996009839A1 PCT/JP1995/001979 JP9501979W WO9609839A1 WO 1996009839 A1 WO1996009839 A1 WO 1996009839A1 JP 9501979 W JP9501979 W JP 9501979W WO 9609839 A1 WO9609839 A1 WO 9609839A1
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin
human
immunoglobulin preparation
preparation
preparation according
Prior art date
Application number
PCT/JP1995/001979
Other languages
English (en)
Japanese (ja)
Inventor
Tuyoshi Takahashi
Kenmi Miyano
Hideo Nishimaki
Koichi Irie
Toshiyuki Saki
Shinji Tomioka
Original Assignee
The Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Green Cross Corporation filed Critical The Green Cross Corporation
Publication of WO1996009839A1 publication Critical patent/WO1996009839A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Definitions

  • the present invention relates to an immunoglobulin preparation excellent in safety, and particularly to an immunoglobulin preparation for intramuscular injection. Background technology
  • Immunoglobulin is a generic name for antibodies and proteins that have structural and functional relationships with them, and is also called imnoglobulin (abbreviated as Ig). It is present in the body fluids of all vertebrates, from fish to mammals, and is produced by lymphoid cells (plasma cells). Classified into five classes (G, M, A, D, E) based on their physicochemical or immunological properties. The basic structure of the molecule is common to each class, and consists of a heavy chain with a molecular weight of 50,000 to 70,000 and a light chain with 23,000. Since each class is a collection of a wide variety of antibodies, there are antibodies that have the same specificity even if the classes are different. In addition, immunoglobulins belonging to the same class have partially different structures depending on the reaction specificity with antigens. Thus, immunoglobulins are a mixture of very diverse proteins.
  • Immunoglobulin preparations are a combination of normal immunoglobulin preparations prepared from pooled plasma, immunoglobulin preparations consisting of immunoglobulins with particularly high antibody titers to specific antigens, and immunoglobulin and other substances Immunoglobulin preparations, and immunoglobulin preparations collected from plasma obtained by immunizing animals, and so-called special immunoglobulin preparations.
  • immunoglobulin preparations Depending on the route of administration, there are preparations for intramuscular administration (intramuscular injection) and preparations for intravenous administration (intravenous injection).
  • Intravenous preparations include non-chemically modified preparations, chemically modified preparations, and enzyme-treated preparations depending on the manufacturing method.
  • Non-chemically modified preparations include polyethylene glycol (PEG) treated preparations, pH 4 treated preparations, and ion exchanger treated preparations.
  • Chemically modified products include alkylated products and sulfonated products.
  • Enzyme-treated preparations include plasmin-treated preparations, pepsin-treated preparations, and tribsine-treated preparations. These immunoglobulin preparations are strictly regulated according to the “Biological Preparation Standards” supervised by the Pharmaceutical Affairs Bureau, Ministry of Health and Welfare.
  • immunoglobulin contains a large amount of antibodies such as viruses and bacteria, it is widely used as an immunoglobulin preparation for the prevention and treatment of infectious diseases.
  • Immunoglobulin preparations which are plasma protein preparations, are generally produced from human or other mammalian plasma. However, it is possible that various contaminating viruses may be present in the plasma of humans or other mammals that are the raw materials for immunoglobulin preparations.
  • HCV hepatitis C virus
  • An object of the present invention is to provide a safer immunoglobulin preparation, particularly an immunoglobulin preparation for intramuscular injection, which can be obtained efficiently and with good operability against virus infection. It is in. Disclosure of the invention
  • the present inventors conducted various studies in consideration of the above circumstances, and found that immunoglobulin preparations, particularly immunoglobulin preparations for intramuscular injection, were more safe against virus infection, especially HCV infection.
  • the present inventors have found that it is possible to develop a formulation having a high level of performance and completed the present invention.
  • the present invention is an immunoglobulin preparation having a negative HCV genome, particularly an immunoglobulin preparation for intramuscular injection.
  • HCV genome negative indicates a level of HCV genome amount of 1 PCR unit (or CID 50 ) / ml or less.
  • One of the preferred examples of "negative HCV genome” is that the amount of HCV genome is less than 1 PCR unit Zm1 in 0.1 to 15 wZv% immunoglobulin solution.
  • HCV genome negative J other, in a one favored correct example, in which the removal rate of the HCV genome indicates 1 0 3 or more.
  • the method of measuring and calculating the “removal rate of the HCV genome” in the present invention is not particularly limited.
  • the PCR unit value of the immunoglobulin-containing solution before the preparation of the immunoglobulin preparation of the present invention and the immune unit of the present invention The method by comparing the PCR unit values of the glopurin preparation is most preferable.
  • immunoglobulin preparations for intramuscular injection there is a very low possibility of virus contamination due to screening of the source plasma and alcohol fractionation, indicating that the preparations are highly safe even from an epidemiological point of view. It is said.
  • immunoglobulin preparations for intramuscular injection do not incorporate PEG fractionation, heat treatment or SD treatment, and the possibility of virus contamination cannot be completely ruled out.
  • porous hollow fibers As a new virus removal method (or inactivation method) is attracting attention [Japanese Journal of Transfusion Medicine Medicine, No. 34, Vol. 6, pp. 615-617. 198 8 (Japananese Journalof Transfusion Medicine, 34 (6) 6 15-6 17 (1 988))].
  • the porous hollow fiber has a very fine pore size and therefore has poor protein permeability, and it is difficult to perform membrane filtration using a porous hollow fiber without using a high-molecular-weight protein or a high-concentration protein solution. It was difficult, and it was necessary to consider various conditions in order to improve the permeation performance.
  • Preferred examples of the method for producing the immunoglobulin preparation of the present invention include: Guropuri down-containing solution Hitahama porous hollow fibers the average pore diameter. 1 to 1 0 0 nm respect, a method of performing 4-5 Te 0, the membrane filtration treatment with ⁇ pressure 0. 1 ⁇ 1 kgf / cm 2 Are mentioned.
  • the immunoglobulin-containing solution which is the starting material for this production method, is not particularly limited as long as it basically contains immunoglobulin as a main component.
  • the immunoglobulin contained as an active ingredient in the immunoglobulin preparation obtained by this production method is highly purified to the extent that it is used as a pharmaceutical.
  • Specific starting materials include those derived from human or plasma plasma and derived from the immunoglobulin fraction.
  • a fraction II obtained from the ethanol fraction of corn from plasma or an equivalent paste containing immunoglobulin and the like can be mentioned.
  • the II fraction or the II + III fraction of the colon which is a raw material of the immunoglobulin preparation
  • this production method can be applied to an immunoglobulin preparation comprising an immunoglobulin having an especially high antibody titer to a specific antigen, an immunoglobulin preparation in which the immunoglobulin is complexed with another substance, a so-called special immunoglobulin preparation. Is effective.
  • anti-HBs human immunoglobulin containing a high unit of high HBs antibody (trade name “Hespulin”, manufactured by Green Cross), anti-tetanus human immunoglobulin containing a high unit of tetanus antitoxin
  • Anti-D (Rh0) immunoglobulin (trade name "anti-D human immunity") containing high units of anti-D (Rh0) antibody
  • high-titer anti-CMV (cytomegalovirus) antibody anti-CMV human immunoglobulin
  • high-titer anti-human lymphocyte antibody Anti-immunoglobulin (trade name “Albulin”, manufactured by Green Cross) or histamine-added human immunoglobulin (trade name “Histobrin”, manufactured by Green Cross)
  • an intramuscular formulation is exemplified as a particularly preferred embodiment, but the present invention is not limited to this.
  • an intravenous formulation is also an embodiment of the present invention. Is exempl
  • Porous hollow fiber Various other requirements can be selected for the porous hollow fiber used in the membrane filtration treatment of this production method as long as the above conditions are satisfied.
  • the material of the porous hollow fiber is not particularly limited, but is preferably a regenerated cellulose.
  • the porous hollow fiber of the regenerated cellulose is preferably subjected to a microphase separation method [American Chemical Society (Am. Chem. Soc.), 9, 1997—22] from a cellulose ammonia solution. 8 (19985)].
  • the average pore size of the porous hollow fiber is from 1 to 100 nm, preferably from 10 to 75 nm, more preferably from 10 to 50 nm, particularly preferably 35 ⁇ 2 nm or 15 ⁇ 2 nm, the inner diameter of the hollow fiber is preferably 330 ⁇ 30 m, the film thickness is preferably 35 ⁇ 3.5 / m or 27 ⁇ 3; um, and the film is preferably hired. Structure.
  • the porous hollow fiber is preferably used in the form of a module.
  • the module is configured by an adhesive to integrate the porous hollow fiber and container for Takashi ⁇ this and these having the film structure of the membrane area 0. 0 l ⁇ lm 2.
  • the solution containing the immunoglobulin in (1) is immersed in the membrane consisting of the porous hollow fiber in (2) and filtered.
  • the immunoglobulin-containing solution is adjusted to a protein concentration of about 0.1 to 15 wZv%.
  • the pH of the solution is particularly adjusted to about 6.4 to 7.2.
  • Filtration pressure is 0. 1 ⁇ 1 1 ⁇ 2 ⁇ ⁇ ⁇ 2, is favored properly 0. 1 ⁇ 0. 5 kgf Z cm 2 or so, more preferred properly is 0. 1 ⁇ 0. 3 kgfcm 2.
  • the processing temperature is 4 to 50 ° C, preferably 30 to 40 ° C (:, more preferably 35 to 37 ° C.
  • a cross-floor pass-through method in which a fluid is strained while giving a strain rate
  • a dead-end method in which a fluid passes without a strain rate.
  • a method using pressurized air is used.
  • the film transfer process under the conditions of the above manufacturing method can be performed a plurality of times.
  • the immunoglobulin-containing solution to be treated by this production method the immunoglobulin-containing solution is preliminarily prepared before the membrane filtration step under the above conditions.
  • those which have been subjected to filtration treatment with a hollow fiber membrane filtration or a flat membrane filtration membrane or the like can be used.
  • the immunoglobulin preparation of the present invention is further formulated or its dosage is adjusted according to the intended efficacy.
  • Examples of the dispensing method include a method in which various antigens and antibodies are made negative, and a method in which amino acids. Sugars, sugar alcohols, inorganic salts, and other additives are added. By preparing a dry preparation, storage for a longer period can be performed.
  • the immunoglobulin preparation of the present invention is effective in preventing the onset of various infectious and allergic diseases and in reducing the symptoms.
  • the dose and frequency of administration of the immunoglobulin preparation of the present invention are appropriately adjusted and studied depending on the composition of the preparation, the patient's symptoms, age, body weight, and the like.
  • B MM Porous hollow fiber [Bemberg Microcroporous Membrane] made from cuprammonium regenerated cellulose as raw material 0.001 to 1. O m 2 Having.
  • a BMM module with an average pore size of 35 nm was used.
  • the BMM module with an average pore diameter of 35 nm (trade name: Planova 35) has an average pore diameter of 35 ⁇ 2 nm, and the membrane layer has a multilayer structure with a multilayer structure of more than 150 expansions. 0 ⁇ 30 im, hollow fiber membrane with a thickness of 35 ⁇ 3.5 m and a polycarbonate capable of high-pressure steam sterilization
  • the autoclave sterilized product is composed of a plastic container made of Bonnet and a polyurethane adhesive that integrates them, and the module is filled with distilled water for injection.
  • the safety of the various materials that make up Branova has been confirmed by the method specified by the Japanese Pharmacopoeia (BMM product description damage).
  • a sample obtained by adding HCV-positive plasma to a 5 wZv% immunoglobulin solution was adjusted to have a pH of 6.4 to 7.2. After removing bacteria (filtration through a membrane filter with a pore size of 0.2 m and membrane filter), the membrane is filtered for 35 to 37 times at a filtration pressure of 0.2 kgf Z cm 2 for 1 to 5 hours. (A dead-end method using air pressure). After cooling, sterilization filtration was performed again, and the mixture was dispensed to prepare a human immunoglobulin preparation for intramuscular injection.
  • the HCV genome in the solution before and after the treatment of this sample was measured by the PCR method.
  • the PCR method in this test was performed by a nested (double) [Nested (Double)] reverse transcription polymerase chain reaction. This method involves the steps of extracting RNA from a test sample, preparing (HCV) cDNA, analyzing NestedPCR and analyzing the PCR product by dot hybridization or PAGE.
  • RNA from Sample As reagents, guanidine, guanidine thiosinate, sarkosyl, phenol, black-mouthed form, and isoamyl alcohol were used. The reaction conditions were room temperature.
  • HCV primer 5 ′ non-coding region
  • Taq polymerase 5 ′ non-coding region
  • the reaction conditions were at least 42 times and at least 20 cycles, and the annealing Lingno PCR was repeated twice.
  • intramuscular for immune Guropuri emissions formulation adjusted before immunization Guropuri emissions containing solvent solution of the present invention is what was 1 0 3 PCR unit 1, the formulation of the present invention is below the detection limit Nima Dropped.
  • Example 1 was performed using the immunoglobulin G fraction obtained by fractionating healthy human plasma containing high units of tetanus antitoxin immunized with tetanus toxoid by the low temperature ethanol method of corn as a starting material. In the same manner as described above, an anti-tetanus human immunoglobulin preparation for intramuscular injection was prepared.
  • Example 1 was performed using the immunoglobulin G fraction obtained by fractionating healthy human plasma containing a high unit of anti-D (Rh0) antibody by the cryogenic ethanol method of corn as a starting material. In the same manner as described above, an anti-D (R h0) human immunoglobulin preparation for intramuscular injection was prepared.
  • Healthy human plasma was subjected to membrane filtration in the same manner as in Example 1 using the immunoglobulin G fraction obtained by fractionating corn by the low-temperature ethanol method as a starting material.
  • a sample obtained by adding HCV-positive plasma to a 5 w / v% immunoglobulin solution was subjected to membrane filtration under the conditions of the present invention (Example 1), and the HCV genome in the solution before and after treatment of this sample was measured by PCR. did.
  • treatment before those were 1 0 3 PCR units / m 1, after treatment beat low to below the detection limit.
  • the recovery rate of the immunoglobulin preparation for intramuscular injection according to the present invention is determined by using the It was 98% or more with respect to the solution, and it was confirmed that there was no change in properties such as molecular weight distribution, IgG subclass distribution, and antibody titer before and after the treatment.
  • the immunoglobulin preparation for intramuscular injection prepared according to this example was stored at 25 ° C for 6 power months, and a stability test was performed.
  • thermostability was good and there was no change in properties such as molecular weight distribution, IgG subclass distribution, and antibody titer.
  • the measurement was carried out by Procedure I (high sensitivity method) using Toxicolor and Endosc Kit (Seikagaku Corporation).
  • the sample used had been subjected to perchloric acid treatment and deproteinized as a pretreatment, and the absorption was measured at 545 nm using diazo force coupling after the main reaction was completed.
  • the endotoxin level is measured by the endotoxin, and the endotoxin-like substance (; 3-1.3-glucan) value is obtained by subtracting the endotoxin measurement from the toxin capacity measurement.
  • the immunoglobulin preparation for intramuscular injection of the present invention remained low before and after the treatment in any case, and the value did not increase after the treatment.
  • the total amount of DNA in the immunoglobulin preparation for intramuscular injection of the present invention was measured using a threshold (Threeshord) system [Morekiula Devices (Molecula Devices)]. DNA was extracted using a DNA extraction kit (Wako Pure Chemical Industries, Ltd.) according to the sample attached to the kit.
  • the total DNA amount in the immunoglobulin preparation for intramuscular injection was below the detection limit (40 pg / m 1) in each case.
  • the concentration of immunoglobulin for intramuscular injection was 15 wZv%.
  • the immunoglobulin fraction obtained by fractionating and recovering the plasma of a mouse containing anti-human lymphocyte antibodies obtained by immunizing the mouse with the human lymphocytes was used as a starting material.
  • the membrane was subjected to membrane filtration in the same manner as in Example 1 to prepare an anti-human lymphocyte / antibody immunoglobulin preparation for intravenous injection.
  • Example 7 The immunoglobulin fraction obtained by fractionating and recovering the plasma of a mouse containing anti-human lymphocyte antibodies obtained by immunizing the mouse with the human lymphocytes was used as a starting material.
  • the membrane filtration treatment was carried out in the same manner as in Example 1 to prepare an anti-human lymphocyte / antibody immunoglobulin preparation for intravenous injection.
  • HCV spike test A sample obtained by adding HCV-positive plasma to a 5 w / v% solution of the anti-human immunoglobulin immunoglobulin disclosed in Example 6 was subjected to membrane filtration according to Example 6, and before and after the sample was processed. The amount of HCV genome in the solution was measured by the PCR method. As a result, those before the treatment was 1 0 3 PCR units Z m 1 is after treatment was reduced to below the detection limit.
  • the immunoglobulin preparation of the present invention particularly the immunoglobulin preparation for intramuscular injection, has an extremely small HCV genomic amount, it is expected that the risk of HCV infection is low and the safety is further improved.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Préparation plus sûre d'immunoglobuline, notamment de l'immunoglobuline destiné à une injection intramusculaire, obtenue selon un procédé d'élaboration efficace et aisée, et sans risque de contamination virale. La préparation a une réaction négative au génome du virus de l'hépatite C (HVC) tout en présentant une concentration du génome de HVC d'au moins une unité de PCR/ml dans une solution d'immunoglobuline à 0,1 à 15 % en poids, et un taux d'élimination du génome de HVC de 103 ou plus.
PCT/JP1995/001979 1994-09-28 1995-09-28 Preparation d'immunoglobuline WO1996009839A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6/257335 1994-09-28
JP25733594 1994-09-28

Publications (1)

Publication Number Publication Date
WO1996009839A1 true WO1996009839A1 (fr) 1996-04-04

Family

ID=17304939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/001979 WO1996009839A1 (fr) 1994-09-28 1995-09-28 Preparation d'immunoglobuline

Country Status (1)

Country Link
WO (1) WO1996009839A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124437A (en) * 1997-03-19 2000-09-26 Welfide Corporation Immunoglobulin preparation and preparation process thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, Vol. 104, No. 6, (1993), YAMAMOTO A.M. et al., pp. 1762-1767. *
J. MED. VIROL., Vol. 43, No. 4, (1994), EL-BATANONY M.H. et al., pp. 380-385. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124437A (en) * 1997-03-19 2000-09-26 Welfide Corporation Immunoglobulin preparation and preparation process thereof

Similar Documents

Publication Publication Date Title
Kimman et al. Local and systemic antibody response to bovine respiratory syncytial virus infection and reinfection in calves with and without maternal antibodies
US11013794B2 (en) Method for preparing foot-and-mouth disease vaccines
JP3297433B2 (ja) ウイルスで汚染された薬理組成物中のウイルスの不活性化方法
US5548066A (en) Failure of passive transfer immune serum and method of making same
US4542016A (en) Non-a non-b hepatitis surface antigen useful for the preparation of vaccines and methods of use
JP2008500959A (ja) ウイルスについて安全な免疫グロブリンの製造方法
US5371196A (en) Process for producing secretory immunoglobulin A preparations
SK287633B6 (sk) Spôsob výroby humánneho gamaglobulínu G a humánny gamaglobulín G s inaktivovanými vírusmi
CN111471103A (zh) 一种新冠病毒（2019-nCOV）的异源抗体及其制备方法
KR19990037317A (ko) 실온 저장가능한 정맥내 주사용 면역글로불린 제제
JPS6262153B2 (fr)
US4199450A (en) Process of separating from an aqueous medium a protein or a morphologically organized unit by liquid exclusion chromatography
EA010057B1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
EP0102731A2 (fr) Méthodes de préparation de gamma globulines exemptes de l'antigène de surface de l'hépatite B et produits
US6962700B1 (en) Method of manufacturing immune globulin
CN116731162B (zh) 人免疫球蛋白生产工艺
WO1996009839A1 (fr) Preparation d'immunoglobuline
US20240024459A1 (en) Method for producing an antigen corresponding to the inactivated sars-cov-2 virus, antigen corresponding to the inactivated sars-cov-2 virus, antigenic composition, kits, and uses thereof
US5419906A (en) Preparation of human immunoglobulin free of hepatitis C
Scheiblauer et al. Prevalance of hepatitis C virus in plasma pools and the effectiveness of cold ethanol fractionation
TWI526214B (zh) 缺乏一種以上致血栓因子的血漿製品之製備方法
JPH0825903B2 (ja) γ―グロブリン含有水溶液
JPH07215891A (ja) 筋注用グロブリン製剤の製造方法
JP4003235B2 (ja) 静注用免疫グロブリン製剤の製造方法
Pöri Development of vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BE CH DE DK ES FR GB IT NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase